Cardiac disease in pregnancy and dilated cardiomyopathy
|
Cardiac disease in pregnancy Microchapters |
|
Diagnosis |
|---|
|
Catheterization: |
|
Treatment |
|
Special Scenarios:
|
|
Cardiac disease in pregnancy and dilated cardiomyopathy On the Web |
|
American Roentgen Ray Society Images of Cardiac disease in pregnancy and dilated cardiomyopathy |
|
FDA on Cardiac disease in pregnancy and dilated cardiomyopathy |
|
CDC on Cardiac disease in pregnancy and dilated cardiomyopathy |
|
Cardiac disease in pregnancy and dilated cardiomyopathy in the news |
|
Blogs on Cardiac disease in pregnancy and dilated cardiomyopathy |
|
Directions to Hospitals Treating Cardiac disease in pregnancy |
|
Risk calculators and risk factors for Cardiac disease in pregnancy and dilated cardiomyopathy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Anjan K. Chakrabarti, M.D. [2]
Overview
Patients with pre-existing cardiomyopathies such as dilated cardiomyopathy and hypertrophic cardiomyopathy, often have significant difficulty dealing with the physiologic and hemodynamic changes that occur during pregnancy, labor, and delivery. In addition to these patients, there is a subset of patients who will develop peripartum cardiomyopathy.
Epidemiology and Demographics
Incidence
Currently, DCM is responsible for "approximately 10,000 deaths and 46,000 hospital stays each year in the United States and is the most common indication for cardiac transplantation."[1]
Cause
The cause often remains unknown, in up to 50% of cases.[2]
Reasons why Women with Dilated Cardiomyopathy are Advised to Avoid Pregnancy
- Dilated cardiomyopathy has been associated with A-type lamin gene defects, which are associated with a high rate of heart failure and life-threatening arrhythmias, as predicted by NYHA functional class[3]
- The increase in intravascular volume and cardiac output during pregnancy leads to a greater risk for complications in women with dilated cardiomyopathy, especially in the 3rd trimester
- A history of cardiac events including previous episodes of heart failure, atrial fibrillation or atrial flutter, transient ischemic attack, or a history of cardiac events before pregnancy is predictive of negative pregnancy-related cardiac outcomes[4]
Treatment
Medical Therapy
Management of Heart Failure
The following should be considered when managing heart failure during pregnancy:[5]
- Goals are similar to non-pregnant patients, including continuation of chronic therapies (with a few exceptions, including discontinuing ACE inhibitors, angiotensin receptor blockers, and aldosterone antagonists).
- Beta-blockers can and should be continued through pregnancy.
- Vasodilator therapy can be safely achieved with amlodipine and hydralazine.
- Sodium restriction and digoxin can both be used during pregnancy.
- In the setting of acute decompansation, intravenous diuretics, vasodilators such as hydralazine, and monitoring with right heart cathterization are all acceptable.
Management during Labor and Delivery
Finally, the following should be considered during labor and delivery:[5]
- Multi-disciplinary approach is crucial.
- Careful maternal continuous monitoring should be employed, including EKG monitoring, non-invasive blood pressure monitoring, and right heart catheterization/arterial line monitoring if necessary.
- No official recommendation on timing of delivery is established; coordination between the obstetrician and cardiologist is necessary to deem what is safest for the patient.
- Vaginal delivery generally poses less cardiovascular risk than cesarian section (less blood loss).
- Induction of labor with an unfavorable cervix should be avoided; induction with a favorable cervix can be achieved with oxytocin and artificial rupture of membranes.
- Epidural anesthesia, can produce changes in preload and afterload that can be advantageous in the setting of reduced ventricular function, and should be considered along with intravenous opiates to provide analgesia and reduce the hemodynamic demands that accompany significant pain.
- When in labor, the patient should be placed in a left lateral decubitus position to avoid IVC compression by the gravid uterus, and the first stage of labor should occur without maternal assistance to avoid the hemodynamic effects of the valsalva maneuver.
- The second stage of labor can be shortened via assistance with low forceps or by vacuum extraction as needed.
Related Chapter
This section will primarily focus on dilated cardiomyopathy (DCM) in pregnancy. For a more detailed discussion of dilated cardiomyopathy, click here.
References
- ↑ Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, Bristow JD, Michels VV; et al. (1992). "Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop". Am J Cardiol. 69 (17): 1458–66. PMID 1590237.
- ↑ Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL; et al. (2000). "Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy". N Engl J Med. 342 (15): 1077–84. doi:10.1056/NEJM200004133421502. PMID 10760308.
- ↑ Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A; et al. (2008). "Long-term outcome and risk stratification in dilated cardiolaminopathies". J Am Coll Cardiol. 52 (15): 1250–60. doi:10.1016/j.jacc.2008.06.044. PMID 18926329.
- ↑ Siu SC, Colman JM, Sorensen S, Smallhorn JF, Farine D, Amankwah KS; et al. (2002). "Adverse neonatal and cardiac outcomes are more common in pregnant women with cardiac disease". Circulation. 105 (18): 2179–84. PMID 11994252.
- ↑ 5.0 5.1 Stergiopoulos K, Shiang E, Bench T (2011). "Pregnancy in patients with pre-existing cardiomyopathies". J Am Coll Cardiol. 58 (4): 337–50. doi:10.1016/j.jacc.2011.04.014. PMID 21757110.